161 related articles for article (PubMed ID: 24736457)
1. Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.
Eisfeld AK; Schwind S; Patel R; Huang X; Santhanam R; Walker CJ; Markowitz J; Hoag KW; Jarvinen TM; Leffel B; Perrotti D; Carson WE; Marcucci G; Bloomfield CD; de la Chapelle A
Sci Signal; 2014 Apr; 7(321):ra36. PubMed ID: 24736457
[TBL] [Abstract][Full Text] [Related]
2. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
Eisfeld AK; Marcucci G; Maharry K; Schwind S; Radmacher MD; Nicolet D; Becker H; Mrózek K; Whitman SP; Metzeler KH; Mendler JH; Wu YZ; Liyanarachchi S; Patel R; Baer MR; Powell BL; Carter TH; Moore JO; Kolitz JE; Wetzler M; Caligiuri MA; Larson RA; Tanner SM; de la Chapelle A; Bloomfield CD
Blood; 2012 Jul; 120(2):249-58. PubMed ID: 22529287
[TBL] [Abstract][Full Text] [Related]
3. Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.
Eisfeld AK; Marcucci G; Liyanarachchi S; Döhner K; Schwind S; Maharry K; Leffel B; Döhner H; Radmacher MD; Bloomfield CD; Tanner SM; de la Chapelle A
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6668-73. PubMed ID: 22493267
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
[TBL] [Abstract][Full Text] [Related]
5. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
Alachkar H; Santhanam R; Maharry K; Metzeler KH; Huang X; Kohlschmidt J; Mendler JH; Benito JM; Hickey C; Neviani P; Dorrance AM; Anghelina M; Khalife J; Tarighat SS; Volinia S; Whitman SP; Paschka P; Hoellerbauer P; Wu YZ; Han L; Bolon BN; Blum W; Mrózek K; Carroll AJ; Perrotti D; Andreeff M; Caligiuri MA; Konopleva M; Garzon R; Bloomfield CD; Marcucci G
J Clin Invest; 2014 Apr; 124(4):1512-24. PubMed ID: 24590286
[TBL] [Abstract][Full Text] [Related]
6. shRNA-Mediated BAALC knockdown affects proliferation and apoptosis in human acute myeloid leukemia cells.
Xu B; Chen G; Shi P; Guo X; Xiao P; Wang W; Zhou S
Hematology; 2012 Jan; 17(1):35-40. PubMed ID: 22549446
[TBL] [Abstract][Full Text] [Related]
7. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
8. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
9. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.
Rücker FG; Russ AC; Cocciardi S; Kett H; Schlenk RF; Botzenhardt U; Langer C; Krauter J; Fröhling S; Schlegelberger B; Ganser A; Lichter P; Zenz T; Döhner H; Döhner K; Bullinger L
Leukemia; 2013 Feb; 27(2):353-61. PubMed ID: 22810507
[TBL] [Abstract][Full Text] [Related]
10. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Schwind S; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Holland KB; Margeson D; Becker H; Whitman SP; Wu YZ; Metzeler KH; Powell BL; Kolitz JE; Carter TH; Moore JO; Baer MR; Carroll AJ; Caligiuri MA; Larson RA; Bloomfield CD
Blood; 2010 Dec; 116(25):5660-9. PubMed ID: 20841507
[TBL] [Abstract][Full Text] [Related]
11. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
Fu L; Shi J; Liu A; Zhou L; Jiang M; Fu H; Xu K; Li D; Deng A; Zhang Q; Pang Y; Guo Y; Hu K; Zhou J; Wang Y; Huang W; Jing Y; Dou L; Wang L; Xu K; Ke X; Nervi C; Li Y; Yu L
Int J Cancer; 2017 Feb; 140(3):653-661. PubMed ID: 27770540
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
[TBL] [Abstract][Full Text] [Related]
13. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
[TBL] [Abstract][Full Text] [Related]
14. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Langer C; Radmacher MD; Ruppert AS; Whitman SP; Paschka P; Mrózek K; Baldus CD; Vukosavljevic T; Liu CG; Ross ME; Powell BL; de la Chapelle A; Kolitz JE; Larson RA; Marcucci G; Bloomfield CD;
Blood; 2008 Jun; 111(11):5371-9. PubMed ID: 18378853
[TBL] [Abstract][Full Text] [Related]
15. A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia.
Bi L; Zhou B; Li H; He L; Wang C; Wang Z; Zhu L; Chen M; Gao S
BMC Cancer; 2018 Feb; 18(1):182. PubMed ID: 29439669
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous changes in expression levels of BAALC and miR-326: a novel prognostic biomarker for childhood ALL.
Ghodousi ES; Aberuyi N; Rahgozar S
Jpn J Clin Oncol; 2020 Jun; 50(6):671-678. PubMed ID: 32129446
[TBL] [Abstract][Full Text] [Related]
17. AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.
Nakagawa M; Shimabe M; Watanabe-Okochi N; Arai S; Yoshimi A; Shinohara A; Nishimoto N; Kataoka K; Sato T; Kumano K; Nannya Y; Ichikawa M; Imai Y; Kurokawa M
Blood; 2011 Dec; 118(25):6626-37. PubMed ID: 22021368
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia.
Palma CA; Al Sheikha D; Lim TK; Bryant A; Vu TT; Jayaswal V; Ma DD
Mol Cancer; 2014 Apr; 13():79. PubMed ID: 24708856
[TBL] [Abstract][Full Text] [Related]
19. Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.
Su YL; Wang X; Mann M; Adamus TP; Wang D; Moreira DF; Zhang Z; Ouyang C; He X; Zhang B; Swiderski PM; Forman SJ; Baltimore D; Li L; Marcucci G; Boldin MP; Kortylewski M
Blood; 2020 Jan; 135(3):167-180. PubMed ID: 31805184
[TBL] [Abstract][Full Text] [Related]
20. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
